Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoantigen tumor vaccine in advanced gastric cancer
NCT05227378Phase 1Unknown
- Start
- Mar 2022
- Primary completion
- Mar 2025
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Personalized Neoantigen Tumor Vaccine (Yongchang Zhang) in gastric cancer (GC). Primary endpoints: Number of participants with treatment-related adverse events at 100 weeks and Objective Response Rate at 100 weeks. Status: unknown.
02
Drugs
Personalized Neoantigen Tumor Vaccine (Yongchang Zhang)
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05227378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05227378.